KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Net Margin (2019 - 2025)

Historic Net Margin for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to 72.91%.

  • Royalty Pharma's Net Margin fell 698900.0% to 72.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 55.43%, marking a year-over-year decrease of 202100.0%. This contributed to the annual value of 58.79% for FY2024, which is 134100.0% down from last year.
  • As of Q3 2025, Royalty Pharma's Net Margin stood at 72.91%, which was down 698900.0% from 15.66% recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Net Margin registered a high of 145.37% during Q2 2021, and its lowest value of 107.83% during Q4 2022.
  • Over the past 5 years, Royalty Pharma's median Net Margin value was 38.44% (recorded in 2022), while the average stood at 49.88%.
  • As far as peak fluctuations go, Royalty Pharma's Net Margin tumbled by -1171500bps in 2022, and later skyrocketed by 2282100bps in 2023.
  • Royalty Pharma's Net Margin (Quarter) stood at 9.32% in 2021, then crashed by -1257bps to 107.83% in 2022, then soared by 212bps to 120.39% in 2023, then tumbled by -53bps to 56.32% in 2024, then grew by 29bps to 72.91% in 2025.
  • Its Net Margin was 72.91% in Q3 2025, compared to 15.66% in Q2 2025 and 76.28% in Q1 2025.